The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...

GSK has teamed up with the University ... changes in cells in precancerous stages that could form the basis of vaccines to prevent full-blown cancer from developing. The pharma group has pledged ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab ... aged 12 and over who have eosinophilic asthma, a form associated with type 2 inflammation, and whose symptoms ...

The E.W. Scripps Company has entered into a transaction support agreement (TSA) with lenders representing more than 70% of the aggregate principal amount of Scripps' outstanding tranche B-2 term loans ...

Supermicro, Inc. a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge, is introducing a wide range of new systems which are fully optimized for edge and embedded workloads. Several ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...